Track topics on Twitter Track topics that are important to you
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
The study will enroll new subjects (hereafter referred as "de novo" subjects) and rollover subjects from the 31-09-266 double blind study. All de novo subjects must enter the screening period of the study and all rollover subjects must enter Phase 1 of the study. Subjects who are screened and are not required to go through Phase1 will begin with a Phase 2 baseline visit following screening.
Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Not yet recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.
Published on BioPortfolio: 2014-07-24T14:05:45-0400
The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disor...
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia.
The primary objective of this study is to evaluate the efficacy of paliperidone prolonged release relative to another atypical antipsychotic, aripiprazole, in the treatment of symptoms of ...
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored c...
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
The aim of this analysis was to explore the effects of brexpiprazole and aripiprazole on body weight when used as monotherapy to treat schizophrenia and as adjunctive treatment to antidepressant treat...
To conduct an overview to summarize the efficacy and safety of aripiprazole for the treatment of schizophrenia.
Nonadherence to antipsychotic medications for the treatment of schizophrenia is a widely recognized concern, leading to poorer clinical outcomes and higher treatment costs. Long-acting injectable (LAI...
Atypical antipsychotic drugs have some efficacy in alleviating the negative and some cognitive symptoms of schizophrenia but those effects are small and mechanisms of this action are still unknown A f...
Safety and tolerability of long-term treatment with the long-acting antipsychotic aripiprazole lauroxil (AL) were evaluated in patients with schizophrenia.
Any observable response or action of an adolescent.
An adolescent who is receiving long-term in-patient services or who resides in an institutional setting.
Adolescent hospitalized for short term care.
A chronic form of schizophrenia characterized primarily by the presence of persecutory or grandiose delusions, often associated with hallucination.
A type of schizophrenia characterized by abnormality of motor behavior which may involve particular forms of stupor, rigidity, excitement or inappropriate posture.
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...